JP2022538505A5 - - Google Patents
Info
- Publication number
- JP2022538505A5 JP2022538505A5 JP2022526849A JP2022526849A JP2022538505A5 JP 2022538505 A5 JP2022538505 A5 JP 2022538505A5 JP 2022526849 A JP2022526849 A JP 2022526849A JP 2022526849 A JP2022526849 A JP 2022526849A JP 2022538505 A5 JP2022538505 A5 JP 2022538505A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- groups
- composition according
- fatty acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094831 | 2019-07-05 | ||
| CNPCT/CN2019/094831 | 2019-07-05 | ||
| PCT/CN2020/100377 WO2021004422A1 (zh) | 2019-07-05 | 2020-07-06 | 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538505A JP2022538505A (ja) | 2022-09-02 |
| JP2022538505A5 true JP2022538505A5 (enExample) | 2023-07-12 |
Family
ID=74115038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526849A Pending JP2022538505A (ja) | 2019-07-05 | 2020-07-06 | ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230115711A1 (enExample) |
| EP (1) | EP3995134A4 (enExample) |
| JP (1) | JP2022538505A (enExample) |
| KR (1) | KR20220071175A (enExample) |
| CN (2) | CN118105372A (enExample) |
| AU (1) | AU2020309681A1 (enExample) |
| BR (1) | BR112022000155A2 (enExample) |
| CA (1) | CA3149104A1 (enExample) |
| CO (1) | CO2022001218A2 (enExample) |
| IL (1) | IL289586A (enExample) |
| MX (1) | MX2022000287A (enExample) |
| PE (1) | PE20220942A1 (enExample) |
| PH (1) | PH12022550254A1 (enExample) |
| TW (1) | TW202126294A (enExample) |
| WO (1) | WO2021004422A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685566A (zh) * | 2020-12-31 | 2022-07-01 | 江苏挪贝肽医药科技有限公司 | 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法 |
| US20240391942A1 (en) * | 2021-09-30 | 2024-11-28 | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | Halogenated phenylarsine oxide compound and application thereof |
| CN116478954B (zh) * | 2023-02-14 | 2025-06-10 | 中国农业大学 | 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032203A1 (en) * | 2001-07-10 | 2003-02-13 | Sabatini David M. | Small molecule microarrays |
| CN103215269B (zh) * | 2007-07-05 | 2015-01-21 | 诺瓦提斯公司 | 用于治疗病毒感染的dsRNA |
| WO2016172952A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用 |
| WO2019200043A1 (en) * | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
| CA3171783A1 (en) * | 2020-03-31 | 2021-10-07 | Fude HUANG | Deuterated oxophenylarsine compound and use thereof |
| US20240391942A1 (en) * | 2021-09-30 | 2024-11-28 | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | Halogenated phenylarsine oxide compound and application thereof |
-
2020
- 2020-07-03 TW TW109122503A patent/TW202126294A/zh unknown
- 2020-07-06 PH PH1/2022/550254A patent/PH12022550254A1/en unknown
- 2020-07-06 KR KR1020227003749A patent/KR20220071175A/ko not_active Ceased
- 2020-07-06 US US17/624,850 patent/US20230115711A1/en active Pending
- 2020-07-06 CA CA3149104A patent/CA3149104A1/en active Pending
- 2020-07-06 PE PE2022000005A patent/PE20220942A1/es unknown
- 2020-07-06 EP EP20836327.5A patent/EP3995134A4/en active Pending
- 2020-07-06 MX MX2022000287A patent/MX2022000287A/es unknown
- 2020-07-06 WO PCT/CN2020/100377 patent/WO2021004422A1/zh not_active Ceased
- 2020-07-06 AU AU2020309681A patent/AU2020309681A1/en not_active Abandoned
- 2020-07-06 BR BR112022000155A patent/BR112022000155A2/pt not_active Application Discontinuation
- 2020-07-06 JP JP2022526849A patent/JP2022538505A/ja active Pending
- 2020-07-06 CN CN202311755839.1A patent/CN118105372A/zh active Pending
- 2020-07-06 CN CN202080049288.5A patent/CN114555056B/zh active Active
-
2022
- 2022-01-03 IL IL289586A patent/IL289586A/en unknown
- 2022-02-07 CO CONC2022/0001218A patent/CO2022001218A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2653568T3 (es) | Formulaciones de fármacos para la prevención del abuso | |
| AU2014211715B2 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| TWI386209B (zh) | 前列腺素ｅ1之乳化組成物 | |
| JP2007302690A5 (enExample) | ||
| JP2014507429A (ja) | 心血管疾患の治療のための組成物および方法 | |
| JP2023522065A5 (enExample) | ||
| RU2015131700A (ru) | Фармацевтические композиции, включающие производное камптотецина | |
| JP2025515474A5 (enExample) | ||
| RU2009112547A (ru) | Жировая эмульсия (варианты), способ ее получения, эмульгирующий агент и способы стабилизации простагландина и капель жира | |
| JP2024544415A5 (enExample) | ||
| ES2584534A1 (es) | Formulación tópica oftálmica de bosentan | |
| JP2022532965A5 (enExample) | ||
| US11331296B2 (en) | Pheromone compositions and uses thereof | |
| JP6448553B2 (ja) | 経皮投与用外用剤 | |
| US10058526B2 (en) | Compositions containing pheromones for treating behavioural or medical problems linked to the stress of non-human mammals | |
| US12558359B2 (en) | Composition having improved voluntary acceptance | |
| BRPI0614378A2 (pt) | formulações compreendendo fenofibrato e uma estatina, e métodos de tratamento relacionados | |
| WO2021004422A1 (zh) | 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 | |
| JP2009514906A5 (enExample) | ||
| CN108143715A (zh) | 一种氟比洛芬酯注射液 | |
| JP2023540771A (ja) | 炎症性腸疾患を治療する方法 | |
| JP2024525239A5 (enExample) | ||
| KR20140006118A (ko) | 피라졸론 유도체 제제 | |
| US20240315968A1 (en) | Sustained release cancer therapeutics formulations | |
| JP6759203B2 (ja) | 薬物及び他の物質の送達のための経口組成物 |